healthcare
Moderna and Merck Achieve Success in Melanoma Clinical Trials
Moderna and Merck announced successful results from a Phase III clinical trial of their personalized mRNA therapy, Intismeran, which significantly reduces the risk of melanoma recurrence when used in combination with Keytruda.
AS1 News
Involving 1,137 patients, the trial demonstrated statistically significant reduction in tumor spread risk, marking a major milestone in mRNA oncology. Moderna's shares more than doubled, while Merck's stock increased by approximately 10%. This represents the first major success in mRNA cancer treatment, potentially opening new avenues for both companies in oncology therapeutics.
The positive trial outcomes could lead to increased investor confidence and potential future approvals, impacting the companies' market valuations and the broader oncology sector.